BFSG LLC’s CRISPR Therapeutics CRSP Stock Holding History

BFSG LLC’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.2K	Hold	206	–	–	﹤0.01%	565
2026 Q1	$9.8K	Hold	206	–	–	﹤0.01%	560
2025 Q4	$10.8K	Hold	206	–	–	﹤0.01%	538
2025 Q3	$13.4K	Hold	206	–	–	﹤0.01%	516
2025 Q2	$10K	Hold	206	–	–	﹤0.01%	509
2025 Q1	$7.01K	Hold	206	–	–	﹤0.01%	528
2024 Q4	$8.11K	Hold	206	–	–	﹤0.01%	519
2024 Q3	$9.68K	Hold	206	–	–	﹤0.01%	499
2024 Q2	$11.1K	Hold	206	–	–	﹤0.01%	466
2024 Q1	$14K	Hold	206	–	–	﹤0.01%	465
2023 Q4	$12.9K	Buy	+206	New	+$11.4K	﹤0.01%	441

Other funds holding CRSP

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIP

Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

BFSG LLC's CRSP Position: Q2 2026 in Review

BFSG LLC held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 206 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #565.

BFSG LLC first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $14K in Q1 2024. 62 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

BFSG LLC held 206 shares of CRISPR Therapeutics worth $11.2K as of Q2 2026.
BFSG LLC left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of BFSG LLC's portfolio in Q2 2026, its #565 holding.
BFSG LLC first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
BFSG LLC's CRISPR Therapeutics position peaked at $14K in Q1 2024.
62 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on BFSG LLC's 13F filing for Q2 2026, filed 20 Jul 2026.